Methods: NSCLC cell lines with EGFR mutation, PC9 and HCC827, were treated with high concentration of gefitinib and the remaining small population of surviving cells were termed as gefitinib-resistant-persisters (GRPs). HDACs, including HDAC1 until HDAC11, were used as markers of chromatin compaction in GRP of PC9 and HCC827 cells. We injected PC9 cells into immuno-deficient mice and, once the tumor growth, we started the treatment with gefitinib. Gefitinib-resistant tumor (GRT) was established by obtaining the remaining tumor in PC9-injected mice after two weeks of gefitinib treatment.
sions of HDAC1, HDAC2, and HDAC5 in PC9-GRP and HCC827-GRP cells. HDAC1 mRNA and protein were also showed upregulation in PC9-GRT as compared to the naïve PC9 tumor. Importantly, treatment with HDAC inhibitor Trichostatin A increased the sensitivity of PC9 and HCC827 cells, as well as GRP cells, to gefitinib. Furthermore, inhibition of HDAC reduced stem cells factors expressions and reduced sphere numbers of GRP. Finally, HDAC1 was also highly observed in lung cancer biopsy specimens from lung cancer patients with acquired resistance to gefitinib.
Conclusion:
These findings suggest that HDAC inhibition by Trichostatin A might be considered to impairs the CSC features and eventually restores the sensitivity of NSCLC to EGFR-TKI. Background and Aims: p116Rip binds to cytoskeletal components such as myosin, actin, and myosin phosphatase. Although p116Rip is expressed in the lungs, its role in pulmonary disorders has never been investigated. Fibroblasts, in particular, affect pulmonary airway remodeling in asthmatic disease caused by the release of pro-inflammatory cytokines due to eosinophilic inflammation. Among them, GM-CSF contributes to lifetime extension and maintenance of eosinophils causing airway remodeling. We previously observed that CREB phosphorylation in the p38MAP kinase signaling plays an important role in TNF-α-induced GM-CSF secretion (Koga et al.Allergol.Int.2016; 65:406-413) .
Here, we investigated the effects of p116Rip on TNF-α-induced GM-CSF secretion, CREB phosphorylation, and cell motility in human lung fibroblasts.
Methods: TNF-α-induced GM-CSF secretion, phosphorylation of CREB and myosin light chain, and cell motility were each evaluated using ELISA, western blot, and wound healing and migration analysis, respectively.
Results: CREB knockdown in fibroblasts decreased TNF-α-induced GM-CSF secretion. p116Rip knockdown in fibroblasts, using p116Rip-specific siRNA, enhanced TNF-α-induced GM-CSF secretion and CREB phosphorylation. Furthermore, p116Rip knockdown increased myosin light chain phosphorylation and enhanced cell motility after PDGF stimulation.
Conclusion: p116Rip regulates TNF-α-induced GM-CSF secretion by modulating CREB phosphorylation. p116Rip also controls cell motility by regulating myosin light chain phosphorylation. Taken together, the results suggest that p116Rip may play an important role in eosinophilic pulmonary disorders by regulating GM-CSF secretion and cell motility. Background and Aims: There is no obvious treatment for acute respiratory distress syndrome (ARDS), although ARDS is a severe, acute inflammatory response within the lung, characterized by diffuse damage to alveolar-capillary barrier and crawling with protein-rich oedema fluid in airspaces resulting in serious gas-exchange abnormalities. In this study, we investigate whether the administration of novel peptide WKYMVm (Trp-Lys-Met-Val-D-Met), with immune-stimulating properties, protects against oedematous lung inflammation in endotoxin-induced acute lung injury (ALI) mice via activation of interferon-induced transcription factor and signal transducer and activator of transcription (STAT) signalling.
Methods:
The WKYMVm peptide was intraperitoneally injected (2.5 and 5 mg/kg) daily for 4 days and then intratracheally injected lipopolysaccharides from E. coli O26:B6 (1 mg/kg). The After 24 h, the mice was sacrificed and the oedematous lung was analysed. Infiltrated inflammatory cells in bronchoalveolar fluid (BALF) was validated using WrightGiemsa method and H&E staining. The expression of pro-inflammatory cytokines, myeloperoxidase (MPO) activity expressed by neutrophil and nitric oxide (NO) level were measured with ELISA, MPO assay and Griess assay, respectively in BALF or serum. The protein levels of IRF/STAT were determined by Western blot analysis in lung tissues.
Results: After instillation of LPS with WKYMVm, the alveolar congestion, haemorrhage, neutrophil infiltration and alveolar wall thickness were mildly reversed compared with LPS group. The cytokine release and MPO activity were decreased in LPS with WKYMVm treated mice, but not NO production. Moreover, we verified that the WKYMVm reduced the increased protein level of IRF7 and phosphorylation of STAT1 in LPS group, but increased IRF1 was not regulated by WKYMVm.
Conclusion:
We have shown the therapeutic ability of novel peptide WKYMVm and IRF7 and STAT1 are able to a critical signalling intermediator for endotoxin-induced ARDS mice. Methods: For ontogenic study, the lambs were surgically delivered and euthanized either at 128 d gestational age (GA) (n = 7), 150 d full term (n = 9) or sacrificed 1 month after term delivery (n = 9). For infection study, pregnant ewes received ultrasound guided intra-amniotic injections of U. parvum serovar 6 (n = 15) or medium/untreated (n = 8) as controls at 55 d GA. Subsequently the lambs were delivered at 138 d GA. We
